FDA panel rejects experimental weight loss pill

July 15, 2010 By MATTHEW PERRONE , AP Business Writer

(AP) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.

The panel voted 10-6 against Vivus Inc.'s Qnexa citing unknown safety risks of long-term use with the drug. The FDA will consider the panel's ruling and make its own decision on the drug in coming months.

Panelists unanimously agreed the drug helps patients lose pounds, with most reporting more than 10 percent . But those benefits were outweighed by a slew of safety concerns that cropped up in company trials, including memory lapses, , and birth defects.

"Some of these side effects are serious and could be life-threatening and must be weighed against a relatively modest weight loss," said the panel's chair, Kenneth Burman of the Washington Hospital Center.

The vote deals a major blow to the Mountainview, Calif., drugmaker, which is racing to market the first new U.S. prescription weight loss drug in over a decade.

The negative opinion also suggests a higher bar for the company's two California competitors - Arena Pharmaceuticals and Orexigen Therapeutics Inc. - which are schedule to have their own weight loss pills reviewed later this year.

Shares of Vivus were halted ahead of the meeting, but the outcome is sure to sink the company's , which has doubled over the past year on high expectations for the drug. The stock closed at $12.11 on Wednesday.

Shares of Arena Pharmaceuticals rose 13 percent to $4.48 in after-hours trading, extending earlier gains from a positive medical journal review of the company's drug lorcaserin.

Orexigen Therapeutics fell 9 percent to $4.55 in extended trading on a tougher approval environment for the company's drug Contrave.

With U.S. obesity rates nearing 35 percent of the adult population, doctors and patients say new pharmaceutical treatments are needed. And Wall Street analysts say even a modestly effective drug has blockbuster potential.

Qnexa has shown the best weight loss results of the three drugs, but it also had the highest rate of patient dropouts due to the side effects.

Several panelists said they wanted to vote in favor of the drug, but needed more information about its long-term effects on the heart. Qnexa only tracked patients for about a year.

"I don't think we have enough data to say whether these are serious issues or not," said Michael Prochan, a statistician with the National Institutes of Health. "I think if we had had longer follow-up I could have voted the other way."

Panelists who favored the drug said they hoped the FDA would still approve Qnexa, despite the vote results.

"I think if this drug is disapproved we're going to send a very negative signal to the overweight and obese that drives them away from medical treatment," and toward more unproven weight loss methods, said Ed Hendricks, director of the Center for Weight Management in Sacramento.

Even FDA staff expressed surprise at the panel's ruling.

"You got the sense that a lot of people had a little bit of hesitancy," said Eric Coleman, deputy director of the FDA's metabolism division. "They weren't strongly against the drug but they had enough concerns to make them lean towards 'no.'"

Qnexa is a combination of two older drugs: the amphetamine phentermine and topiramate, an anticonvulsant drug sold by Johnson & Johnson as Topamax. According to the company, phentermine helps suppress appetite, while topiramate makes patients feel more satiated.

Vivus representatives told panelists the company's drug fills an important gap between current treatment options.

Current weight loss drugs on the market such as Roche's Xenical and Abbott Laboratory's Meridia offer weight loss in the five percent range. Bariatric surgery can help patients lose 30 to 35 percent, though complications with the operation can be life-threatening.

The quest for a blockbuster weight loss drug has been plagued for decades by safety issues. The most notable was Wyeth's diet pill-drug combination, fen-phen, which was pulled off the market in 1997 because of links to heart-valve damage and lung problems.

shares

Related Stories

Recommended for you

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

Introduction is different, but top medications for opioid addiction equally effective

November 14, 2017
With opioid addiction officially declared a public health emergency in the U.S., medical intervention to treat the illness is increasingly important in responding to the epidemic. Now, a new study concludes that two of the ...

Drugstore pain pills as effective as opioids in ER patients

November 7, 2017
Emergency rooms are where many patients are first introduced to powerful opioid painkillers, but what if doctors offered over-the-counter pills instead? A new study tested that approach on patients with broken bones and sprains ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

eachus
5 / 5 (2) Jul 15, 2010
Whoever wrote this article almost got it right. fen-phen is/was a combination of phentermine and fenfluramine or dextrofenfluramine. Yes, the same phentermine that is one component of this new drug. Even though the heart valve problems with fen-phen were related to the fenfluramine or dextrofenfluramine not the phentermine, I can understand why the FDA panel was a little scared by the reports of severe side effects: "Some of these side effects are serious and could be life-threatening and must be weighed against a relatively modest weight loss," said the panel's chair, Kenneth Burman of the Washington Hospital Center.

I certainly agree, and I see no real need to market what is again a combination of drugs which are already licensed for other uses.
yyz
not rated yet Jul 16, 2010
eachus, I agree, though this decision may lead to increased numbers of prescriptions for this 'off label' combination.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.